Obermatt
See Similar Stocks →

Flags

Financial distress

Codexis

NSQ:CDXS · US1920051067
Life Sciences Tools & ServicesSmall

360

25
Profit price63
Owner Earnings Yield1
Dividend Yield1
Price/Sales64
EV / Gross Profit24
Price/Book5
Return on Capital18
Cash Return on Capital6
Return on Equity12
EBIT Margin28
Gross Profitability40
Accruals77
Owner Earnings Margin22
Sales growth48
Profit growth33
Reinvestment84
Price momentum41
Debt load22
Refinancing39
Debt Payback1
Liquidity31
Analyst ratings46
Opinion Changes50
Price Target Upside94
Market mood37
Value Creation6/20not creating value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Codexis doesn't consistently earn more than its cost of capital, so it isn't yet creating shareholder value.

Profile

CountryUSA
IndustryLife Sciences Tools & Services
SizeSmall
TypePublic Company
ExchangeNASDAQGS
Founded2002
Employees171
Websitecodexis.com
ISINUS1920051067
Last UpdateApr 2, 2026
Indices
NASDAQ (USA)
Themes
Health DiagnosticsBiomedical EngineeringGeneticsBiotechnologyChemicalSustainability

Description

Codexis, Inc. (Codexis) provides technology solutions to improve therapeutics manufacturing. The company discovers, develops, enhances, and commercializes novel, high-performance enzymes and other classes of proteins by leveraging its proprietary Co…

Analysis

Middle-of-the-road

Codexis, Inc. is a middle-of-the-road business: neither the economics nor the price stand out from the peer group.

Valuation data is not available for this company.

The trajectory is moderate and the balance sheet is stretched. The company scores 6/20 on our value-creation score: not creating value. Analysts lean positive.

Nothing is flagged here: no red or amber gates, no divergence between profits and cash. That is itself information: the numbers are straightforward. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
17
2023202420252026

All-time high

91

Jan 2025

All-time low

9

Jan 2023

Average rank

37

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
64
42
56
34
Price/Earnings
71
36
36
36
Price/Book
5
97
52
19
Dividend Yield
1
1
1
1
Value (overall)
30
66
47
21

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Codexis with its peers
OmniAb
NMQ:OABI
61
CountryUSA
IndustryLife Sciences Tools & Services
SizeSmall
Full Stock Analysis →
DiaMedica Therapeutics
NAQ:DMAC
—
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Tempus AI
NSQ:TEM
28
CountryUSA
IndustryLife Sciences Tools & Services
SizeMedium
Full Stock Analysis →
Repligen
NSQ:RGEN
66
CountryUSA
IndustryLife Sciences Tools & Services
SizeLarge
Full Stock Analysis →
Mesa Laboratories
NSQ:MLAB
69
CountryUSA
IndustryLife Sciences Tools & Services
SizeSmall
Full Stock Analysis →
Azenta
NSQ:AZTA
35
CountryUSA
IndustryLife Sciences Tools & Services
SizeMedium
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →